80% of the global burden of cardiovascular disease is located in countries with low or middle incomes. The aim of this study was to demonstrate the contrast in risk factors for cardiovascular disease incidence and mortality in low, medium and high income countries. This study included 155245 patients from 628 cities in 17 countries over…
ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque
Induction apoA-1 synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1 synthesis with favorable effect on HDL cholesterol. The impact of this drug on cholesterol plaque has not been investigated in humans. The objective of this study was to test the effects of RVX-208 100 mg twice a…
SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit
The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined…
EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.
Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on macrovascular complications. This study evaluates the results of alogliptin compared with placebo in patients with type 2 diabetes who had a recent acute coronary syndrome. The…
COMPARE: Losartan shows promising results in patients with Marfan syndrome
Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and sudden death. Current treatment recommends prophylactic surgery when it reaches a measurement between 46-50 mm (IC) or when it is > 50 mm (IIa C) associated with beta-blocker treatment. The role of losartan added to this therapy is…